Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.
Saved in:
| Title: | Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. |
|---|---|
| Authors: | Akhave N; The University of Texas MD Anderson Cancer Center, Houston, TX., Song Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Tricoli JV; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2026 Feb; Vol. 10, pp. e2500612. Date of Electronic Publication: 2026 Feb 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
